# Efficacy and Safety of BN101 in Subjects With Chronic Graft Versus Host Disease (cGVHD)

> **NCT04930562** · PHASE2 · COMPLETED · sponsor: **BioNova Pharmaceuticals (Shanghai) LTD.** · enrollment: 30 (actual)

## Conditions studied

- GVHD, Chronic

## Interventions

- **DRUG:** BN101

## Key facts

- **NCT ID:** NCT04930562
- **Lead sponsor:** BioNova Pharmaceuticals (Shanghai) LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-27
- **Primary completion:** 2022-06-10
- **Final completion:** 2022-12-10
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2024-01-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04930562

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04930562, "Efficacy and Safety of BN101 in Subjects With Chronic Graft Versus Host Disease (cGVHD)". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT04930562. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*